Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Media Gizi Indonesia (MGI)
Cia Aprilianti
Doctoral Program of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
A Prediction Model for Premenstrual Syndrome Treatment Success in Adolescents: The Role of Hemoglobin Recovery and Early Symptom Response Cia Aprilianti; Antono Suryoputro; Martha Irene Kartasurya; Nurjazuli Nurjazuli
Media Gizi Indonesia Vol. 21 No. 4 (2026): MEDIA GIZI INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mgi.v21i4.517-532

Abstract

Approximately 22–65% of adolescent girls experience severe premenstrual syndrome (PMS), yet no validated tool exists to identify non-responders early enough for timely intervention. This study developed and internally validated a model predicting PMS treatment success from early response and hemoglobin recovery. A prospective quasi-experimental three-arm study enrolled 156 girls aged 16–18 years with severe PMS (score ≥121) from three senior high schools in Palangka Raya, Central Kalimantan, Indonesia (October 2024–April 2025). Four logistic regression models were compared using the area under the receiver operating characteristic curve (AUC), McFadden R², and Hosmer–Lemeshow calibration, with optimism correction from 1,000 and 95% confidence intervals from 2,000 bootstrap resamples. Of the 156 participants, 59 (37.8%) met the success criteria. The final model achieved AUC 0.918 (95% CI: 0.873–0.957; optimism-corrected 0.909), with accuracy, sensitivity, and specificity of 85.9%, 83.1%, and 87.6%, respectively. Three predictors emerged: baseline PMS severity (OR = 0.11; 95% CI: 0.05–0.23), cumulative hemoglobin recovery (OR = 3.63; 95% CI: 1.98–6.67), and early symptom change at week 4 (OR = 0.55; 95% CI: 0.32–0.94). The model enables mid-treatment risk stratification from three measurable variables, supporting treatment modification. External validation is essential prior to clinical adoption.  
Co-Authors Antono Suryoputro Martha Irene Kartasurya Nurjazuli Nurjazuli